Creo Medical Group (LON:CREO) Trading 7.5% Higher – Still a Buy?

Shares of Creo Medical Group PLC (LON:CREO) were up 7.5% during mid-day trading on Tuesday . The company traded as high as GBX 20.40 ($0.26) and last traded at GBX 19.99 ($0.25). Approximately 621,117 shares were traded during mid-day trading, a decline of 14% from the average daily volume of 718,493 shares. The stock had previously closed at GBX 18.60 ($0.23).

Creo Medical Group Stock Up 1.5 %

The company’s fifty day simple moving average is GBX 17.57 and its 200 day simple moving average is GBX 24.90. The company has a quick ratio of 2.19, a current ratio of 3.24 and a debt-to-equity ratio of 29.96. The firm has a market capitalization of £71.63 million, a PE ratio of -330.00 and a beta of 0.86.

Insider Transactions at Creo Medical Group

In other Creo Medical Group news, insider Richard John Rees acquired 98,000 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were acquired at an average price of GBX 20 ($0.25) per share, for a total transaction of £19,600 ($24,524.52). Also, insider Kevin Crofton bought 1,179,000 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were acquired at an average cost of GBX 17 ($0.21) per share, with a total value of £200,430 ($250,788.29). In the last quarter, insiders bought 4,193,666 shares of company stock valued at $92,002,984. Corporate insiders own 22.43% of the company’s stock.

About Creo Medical Group

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope.